Thymoma

Researchers are testing whether lucitanib, an oral drug, can slow the growth of advanced thymic carcinoma that has worsened after at least one round of chemotherapy. The trial enrolls adults with recurrent or metastatic thymic carcinoma. In one part, participants receive lucitani…

This early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 43 people with advanced thymic carcinoma or a related thymoma that had worsened after standard chemotherapy. The goal was to see if the combination could stop or slow cancer growth. Participants receiv…

This study tested whether adding the drug ramucirumab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced thymic cancer that cannot be removed by surgery or has spread. Twenty-one participants were randomly assigned to receive chemo with or without ra…

This study looked at whether having a tendency toward depression affects how well people with thymoma-associated myasthenia gravis (MG) respond to psychological counseling. Nineteen adults who had surgery for thymoma and MG received eight sessions of counseling based on Gestalt t…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study reviewed medical records of 100 people with myasthenia gravis who had thymus gland surgery. Researchers compared those with and without a thymus tumor to see what factors helped predict a full recovery. The goal was to better understand who benefits most from this proc…

This study looked at 156 patients with thymic carcinoma, a rare and aggressive chest cancer. Researchers created a tool called a nomogram that uses patient data to predict how long someone might live after diagnosis. The tool was tested on three groups of patients and showed prom…